| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $96,850 | 4 | 100 |
Sells | $0 | 0 | 0 |
| Lerner Neil | Chief Accounting Officer | 3 | $49,600 | 0 | $0 | $49,600 |
| Anderman Jonathan | General Counsel | 1 | $47,250 | 0 | $0 | $47,250 |
Compass Therapeutics, Inc. is a biopharmaceutical firm focused on developing cancer treatments, with several therapeutic candidates currently in clinical trials. The company's work involves creating antibody-based medicines designed to address a variety of human health conditions. Among its leading clinical-stage programs are CTX-009, an experimental bispecific antibody engineered to inhibit the Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, both of which are crucial for the growth of new blood vessels …
Over the last 12 months, insiders at Compass Therapeutics, Inc. have bought $96,850 and sold $0 worth of Compass Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Compass Therapeutics, Inc. have bought $10.41M and sold $5.73M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Lerner Neil (Chief Accounting Officer) — $49,600. Anderman Jonathan (General Counsel) — $47,250.
The last purchase of 20,000 shares for transaction amount of $18,400 was made by Lerner Neil (Chief Accounting Officer) on 2026‑10‑01.
| 2026-10-01 | Lerner Neil | Chief Accounting Officer | 20,000 0.0113% | $0.92 | $18,400 | -7.34% | ||
| 2026-09-24 | Lerner Neil | Chief Accounting Officer | 2,500 0.0014% | $1.14 | $2,850 | -24.36% | ||
| 2026-04-29 | Lerner Neil | Chief Accounting Officer | 15,000 0.0123% | $1.89 | $28,350 | +20.96% | ||
| 2026-04-29 | Anderman Jonathan | General Counsel | 25,000 0.0205% | $1.89 | $47,250 | +20.96% | ||
| 2025-05-27 | Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | 10,000 0.0072% | $2.11 | $21,100 | +92.89% | ||
| 2025-04-09 | Sale | ORBIMED ADVISORS LLC | 3.57M 2.6156% | $1.59 | $5.68M | +113.71% | ||
| 2025-04-09 | Sale | GORDON CARL L | 3.57M 2.6156% | $1.59 | $5.68M | +113.71% | ||
| 2025-04-07 | Lerner Neil | CHIEF ACCOUNTING OFFICER | 20,000 0.0131% | $1.42 | $28,400 | +137.58% | ||
| 2025-04-07 | Anderman Jonathan | Gen Counsel & Corporate Sec | 20,000 0.0142% | $1.54 | $30,800 | +137.58% | ||
| 2023-03-10 | Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | 10,000 0.008% | $3.37 | $33,700 | -31.33% | ||
| 2023-02-27 | Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | 20,000 0.016% | $3.98 | $79,600 | -39.44% | ||
| 2023-02-15 | Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | 20,000 0.0153% | $3.86 | $77,200 | -38.69% | ||
| 2023-01-31 | Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | 20,000 0.016% | $4.05 | $81,000 | -35.75% | ||
| 2023-01-24 | Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | 20,000 0.0158% | $4.19 | $83,800 | -37.29% | ||
| 2022-11-25 | Sale | Bisker-Leib Vered | Chief Operating Officer | 2 <0.0001% | $4.36 | $9 | -28.83% | |
| 2022-11-23 | Sale | Bisker-Leib Vered | Chief Operating Officer | 9,569 0.0088% | $4.30 | $41,147 | -30.00% | |
| 2022-11-22 | Sale | Bisker-Leib Vered | Chief Operating Officer | 14,929 0.0139% | $4.19 | $62,553 | -27.27% | |
| 2022-11-08 | ORBIMED ADVISORS LLC | director | 402,000 0.2887% | $3.21 | $1.29M | -25.18% | ||
| 2022-11-08 | GORDON CARL L | director | 402,000 0.2887% | $3.21 | $1.29M | -25.18% | ||
| 2022-09-07 | Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | 15,000 0.0148% | $3.03 | $45,450 | +4.92% |
| Lerner Neil | Chief Accounting Officer | 420000 0.2332% | $316,260.00 | 4 | 0 | +137.58% |
| Anderman Jonathan | General Counsel | 196000 0.1088% | $147,588.00 | 2 | 0 | +137.58% |
| OrbiMed Genesis GP LLC | 14690178 8.1572% | $11.06M | 2 | 0 | +76.65% | |
| Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | 6480825 3.5987% | $4.88M | 21 | 0 | +11.46% |
| Sunderland Julie | director | 2502025 1.3893% | $1.88M | 1 | 0 | |
| Ferneau Philip | director | 2348976 1.3043% | $1.77M | 1 | 0 | |
| ORBIMED ADVISORS LLC | 0 0% | $0 | 3 | 1 | <0.0001% | |
| GORDON CARL L | 0 0% | $0 | 5 | 1 | +26.53% |
$16,280,851 | 76 | 1.48% | $118.27M | |
$4,898,715 | 46 | 40.75% | $114.69M | |
$6,788,859 | 35 | 26.72% | $151.54M | |
$7,147,964 | 34 | 24.77% | $166.39M | |
$47,438,336 | 33 | -21.38% | $122.37M |
| Increased Positions | 118 | +110.28% | 34M | +22.25% |
| Decreased Positions | 44 | -41.12% | 21M | -13.6% |
| New Positions | 59 | New | 19M | New |
| Sold Out Positions | 11 | Sold Out | 6M | Sold Out |
| Total Postitions | 181 | +69.16% | 164M | +8.65% |
| Tang Capital Management Llc | $86,918.00 | 9.45% | 16.81M | +3M | +24.57% | 2025-09-30 |
| Orbimed Advisors Llc | $78,687.00 | 8.55% | 15.22M | 0 | 0% | 2025-09-30 |
| Suvretta Capital Management, Llc | $72,903.00 | 7.92% | 14.1M | +7M | +97.23% | 2025-09-30 |
| Blackstone Inc. | $50,873.00 | 5.53% | 9.84M | -185,043 | -1.85% | 2025-09-30 |
| Vivo Capital, Llc | $49,350.00 | 5.36% | 9.55M | +4M | +57.95% | 2025-09-30 |
| Enavate Sciences Gp, Llc | $40,265.00 | 4.38% | 7.79M | 0 | 0% | 2025-09-30 |
| Blackrock, Inc. | $38,107.00 | 4.14% | 7.37M | +957,614 | +14.93% | 2025-09-30 |
| Vanguard Group Inc | $36,515.00 | 3.97% | 7.06M | +2M | +45.63% | 2025-09-30 |
| Adage Capital Partners Gp, L.L.C. | $26,814.00 | 2.91% | 5.19M | +761,632 | +17.21% | 2025-09-30 |
| Mpm Bioimpact Llc | $26,243.00 | 2.85% | 5.08M | -546,535 | -9.72% | 2025-09-30 |